TerminatedPhase 4ACTRN12608000398303

Wellness Study

Efficacy of low dose escitalopram v's placebo in the amelioration of anxiety and fatigue in patients who are unwell or suffer chronic illness

Sponsor

Mood Research Foundation (WA)

Enrollment

50 participants

Start Date

Jul 20, 2007

Study Type

Interventional

Conditions

Chronic illness - patients who are generally unwell for an extended period.

Summary

The Wellness Study will evaluate 6 weeks of very low dose Escitalopram (50 micrograms) compared to placebo on fatigue, anxiety and depression in chronic medical illness. Following a 3 week baseline run in-phase, participants will be randomised 'double blind' to the active or placebo treatment, incorporating 4 study centre visits in all. Associated clinical benefits may include improvements in sleep, weight reduction, heart rate and blood pressure. Although serotonin re-uptake inhibitors have never previously been studied at such a low dose, clinical results to date appear encouraging.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 85 Yearss

Plain Language Summary

Simplified for easier understanding

This study is testing a wellness intervention for people who have been unwell with a chronic illness for an extended period. The goal is to see if the treatment can improve overall wellbeing. It is open to adults aged 18 to 85 who have a chronic illness and are not currently taking antidepressants or psychiatric medications.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

0.05mg escitalopram oxalate in a lactose base in an opaque capsule. 1 capsule taken daily via oral route for a period of 6 weeks.

Locations(1)

WA, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000398303